vs
奎斯特诊断（IMDX）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是奎斯特诊断的614.5倍（$699.9M vs $1.1M）。QuidelOrtho Corp净利率更高（-104.7% vs -2015.4%，领先1910.6%）。QuidelOrtho Corp同比增速更快（-3.7% vs -23.4%）。奎斯特诊断自由现金流更多（$-7.0M vs $-94.7M）。过去两年奎斯特诊断的营收复合增速更高（154.4% vs -2.9%）
奎斯特诊断公司是一家美国临床检验企业，跻身财富500强，业务覆盖美国本土，以及波多黎各、墨西哥、巴西等地区，同时与全球多家医院和诊所保持合作关系，是行业内颇具影响力的医疗诊断服务提供商。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
IMDX vs QDEL — 直观对比
营收规模更大
QDEL
是对方的614.5倍
$1.1M
营收增速更快
QDEL
高出19.6%
-23.4%
净利率更高
QDEL
高出1910.6%
-2015.4%
自由现金流更多
IMDX
多$87.7M
$-94.7M
两年增速更快
IMDX
近两年复合增速
-2.9%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $699.9M |
| 净利润 | $-23.0M | $-733.0M |
| 毛利率 | 42.5% | — |
| 营业利润率 | -2057.5% | -100.7% |
| 净利率 | -2015.4% | -104.7% |
| 营收同比 | -23.4% | -3.7% |
| 净利润同比 | 31.5% | -3583.4% |
| 每股收益（稀释后） | $-0.75 | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMDXQDEL
| Q4 25 | $1.1M | — | ||
| Q3 25 | $260.0K | $699.9M | ||
| Q2 25 | $518.0K | $613.9M | ||
| Q1 25 | $2.1M | $692.8M | ||
| Q4 24 | $1.5M | $707.8M | ||
| Q3 24 | $115.0K | $727.1M | ||
| Q2 24 | $104.0K | $637.0M | ||
| Q1 24 | $176.0K | $711.0M |
净利润IMDXQDEL
| Q4 25 | $-23.0M | — | ||
| Q3 25 | $-10.9M | $-733.0M | ||
| Q2 25 | $-9.7M | $-255.4M | ||
| Q1 25 | $-6.7M | $-12.7M | ||
| Q4 24 | $-33.5M | $-178.4M | ||
| Q3 24 | $-13.5M | $-19.9M | ||
| Q2 24 | $-4.5M | $-147.7M | ||
| Q1 24 | $-9.1M | $-1.7B |
毛利率IMDXQDEL
| Q4 25 | 42.5% | — | ||
| Q3 25 | 53.5% | — | ||
| Q2 25 | 67.6% | — | ||
| Q1 25 | 62.0% | — | ||
| Q4 24 | 40.0% | — | ||
| Q3 24 | 43.5% | — | ||
| Q2 24 | 48.1% | — | ||
| Q1 24 | 25.6% | — |
营业利润率IMDXQDEL
| Q4 25 | -2057.5% | — | ||
| Q3 25 | -4249.2% | -100.7% | ||
| Q2 25 | -1900.0% | -29.4% | ||
| Q1 25 | -318.0% | 4.7% | ||
| Q4 24 | -2262.9% | -14.2% | ||
| Q3 24 | -11752.2% | 2.1% | ||
| Q2 24 | -4453.8% | -18.4% | ||
| Q1 24 | -5265.3% | -247.3% |
净利率IMDXQDEL
| Q4 25 | -2015.4% | — | ||
| Q3 25 | -4174.6% | -104.7% | ||
| Q2 25 | -1880.7% | -41.6% | ||
| Q1 25 | -312.0% | -1.8% | ||
| Q4 24 | -2255.1% | -25.2% | ||
| Q3 24 | -11733.0% | -2.7% | ||
| Q2 24 | -4355.8% | -23.2% | ||
| Q1 24 | -5186.9% | -239.9% |
每股收益（稀释后）IMDXQDEL
| Q4 25 | $-0.75 | — | ||
| Q3 25 | $-0.34 | $-10.78 | ||
| Q2 25 | $-0.30 | $-3.77 | ||
| Q1 25 | $-0.26 | $-0.19 | ||
| Q4 24 | $-2.19 | $-2.54 | ||
| Q3 24 | $-0.98 | $-0.30 | ||
| Q2 24 | $-0.36 | $-2.20 | ||
| Q1 24 | $-1.13 | $-25.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.6M | $98.1M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $-31.5M | $2.0B |
| 总资产 | $25.8M | $5.7B |
| 负债/权益比越低杠杆越低 | — | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资IMDXQDEL
| Q4 25 | $11.6M | — | ||
| Q3 25 | $18.7M | $98.1M | ||
| Q2 25 | $24.3M | $151.7M | ||
| Q1 25 | $31.0M | $127.1M | ||
| Q4 24 | $8.6M | $98.3M | ||
| Q3 24 | $3.4M | $143.7M | ||
| Q2 24 | $9.3M | $107.0M | ||
| Q1 24 | $5.6M | $78.5M |
总债务IMDXQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益IMDXQDEL
| Q4 25 | $-31.5M | — | ||
| Q3 25 | $-9.2M | $2.0B | ||
| Q2 25 | $1.1M | $2.8B | ||
| Q1 25 | $10.2M | $3.0B | ||
| Q4 24 | $-12.3M | $3.0B | ||
| Q3 24 | $9.7M | $3.2B | ||
| Q2 24 | $22.7M | $3.2B | ||
| Q1 24 | $11.6M | $3.3B |
总资产IMDXQDEL
| Q4 25 | $25.8M | — | ||
| Q3 25 | $43.9M | $5.7B | ||
| Q2 25 | $50.5M | $6.4B | ||
| Q1 25 | $60.4M | $6.5B | ||
| Q4 24 | $35.1M | $6.4B | ||
| Q3 24 | $70.2M | $6.8B | ||
| Q2 24 | $74.7M | $6.7B | ||
| Q1 24 | $71.0M | $6.7B |
负债/权益比IMDXQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | $-7.0M | $-94.7M |
| 自由现金流率自由现金流/营收 | -616.7% | -13.5% |
| 资本支出强度资本支出/营收 | 129.9% | 7.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-25.4M | $-153.1M |
8季度趋势，按日历期对齐
经营现金流IMDXQDEL
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $-4.5M | $-45.5M | ||
| Q2 25 | $-6.3M | $-46.8M | ||
| Q1 25 | $-5.9M | $65.6M | ||
| Q4 24 | $-5.4M | $63.7M | ||
| Q3 24 | $-5.5M | $117.9M | ||
| Q2 24 | $-6.0M | $-97.9M | ||
| Q1 24 | $-3.8M | $-700.0K |
自由现金流IMDXQDEL
| Q4 25 | $-7.0M | — | ||
| Q3 25 | $-5.6M | $-94.7M | ||
| Q2 25 | $-6.6M | $-84.3M | ||
| Q1 25 | $-6.2M | $9.4M | ||
| Q4 24 | $-5.6M | $16.5M | ||
| Q3 24 | $-5.6M | $71.4M | ||
| Q2 24 | $-6.2M | $-133.2M | ||
| Q1 24 | $-3.9M | $-66.8M |
自由现金流率IMDXQDEL
| Q4 25 | -616.7% | — | ||
| Q3 25 | -2135.4% | -13.5% | ||
| Q2 25 | -1279.5% | -13.7% | ||
| Q1 25 | -288.4% | 1.4% | ||
| Q4 24 | -374.5% | 2.3% | ||
| Q3 24 | -4884.3% | 9.8% | ||
| Q2 24 | -5931.7% | -20.9% | ||
| Q1 24 | -2189.8% | -9.4% |
资本支出强度IMDXQDEL
| Q4 25 | 129.9% | — | ||
| Q3 25 | 403.8% | 7.0% | ||
| Q2 25 | 67.4% | 6.1% | ||
| Q1 25 | 14.4% | 8.1% | ||
| Q4 24 | 14.4% | 6.7% | ||
| Q3 24 | 75.7% | 6.4% | ||
| Q2 24 | 183.7% | 5.5% | ||
| Q1 24 | 13.6% | 9.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMDX
暂无分部数据
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
